Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11.
Saved in:
| Title: | Progression of Stargardt Disease as Determined by Fundus Autofluorescence Over a 12-Month Period: ProgStar Report No. 11. |
|---|---|
| Authors: | Strauss RW; Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.; Moorfields Eye Hospital National Health Services Foundation Trust and UCL Institute of Ophthalmology, University College London, London, United Kingdom.; Department of Ophthalmology, Johannes Kepler University Clinic Linz, Linz, Austria.; Department of Ophthalmology, Medical University Graz, Graz, Austria., Kong X; Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.; Department of Biostatistics and Epidemiology, University of Massachusetts, Amherst., Ho A; Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles., Jha A; Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles., West S; Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland., Ip M; Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles., Bernstein PS; Moran Eye Center, University of Utah School of Medicine, Salt Lake City., Birch DG; Retina Foundation of the Southwest, Dallas, Texas., Cideciyan AV; Scheie Eye Institute, Perelman School of Medicine, University of Pennsylvania, Philadelphia., Michaelides M; Moorfields Eye Hospital National Health Services Foundation Trust and UCL Institute of Ophthalmology, University College London, London, United Kingdom., Sahel JA; Sorbonne Universités, University Pierre et Marie Curie Université de Paris 06, Institut National de la Santé et de la Recherche Médicale, Centre National de la Recherche Scientifique, Institut de la Vision, Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Paris, France., Sunness JS; Hoover Low Vision Rehabilitation Services, Greater Baltimore Medical Center, University of Maryland School of Medicine, Baltimore, Maryland., Traboulsi EI; Cole Eye Institute, Cleveland Clinic, Cleveland, Ohio., Zrenner E; Center for Ophthalmology, Eberhard-Karls University Hospital, Tübingen, Germany., Pitetta S; Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles., Jenkins D; Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles., Hariri AH; Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles., Sadda S; Doheny Eye Institute, David Geffen School of Medicine, University of California, Los Angeles., Scholl HPN; Wilmer Eye Institute, Johns Hopkins University, Baltimore, Maryland.; Institute of Molecular and Clinical Ophthalmology Basel, Basel, Switzerland.; Department of Ophthalmology, University of Basel, Basel, Switzerland. |
| Corporate Authors: | ProgStar Study Group |
| Source: | JAMA ophthalmology [JAMA Ophthalmol] 2019 Oct 01; Vol. 137 (10), pp. 1134-1145. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Medical Association Country of Publication: United States NLM ID: 101589539 Publication Model: Print Cited Medium: Internet ISSN: 2168-6173 (Electronic) Linking ISSN: 21686165 NLM ISO Abbreviation: JAMA Ophthalmol Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2168-6173 |
|---|---|
| DOI: | 10.1001/jamaophthalmol.2019.2885 |
